P=N/A, N=40, Completed, The Fourth Affiliated Hospital of Soochow University (Suzhou Dushuhu Hospital); The Fourth Affiliated Hospital of Soochow University (Suzhou Dushuhu H | Not yet recruiting --> Completed

We developed a biofunctional hybrid scaffold (PMEAR/MM/uEV) combining a porous poly(lactic-co-glycolic acid)-porcine extracellular matrix, ricinoleic acid-modified magnesium hydroxide, metanephric mesenchyme-like cells, and ureteric bud-derived extracellular vesicles, with resveratrol and adapalene to confer antioxidant and pro-regenerative properties...mRNA sequencing revealed activation of angiogenesis, extracellular matrix remodeling, oxidative defense, and immune modulation, with Kyoto Encyclopedia of Genes and Genomes enrichment in tumor necrosis factor and interleukin-17 signaling and nuclear factor kappa B-associated pathways. These findings establish PMEAR/MM/uEV as an effective, multimodal platform for kidney regeneration.

P=N/A, N=64, Completed, University of Medicine and Pharmacy at Ho Chi Minh City

P=N/A, N=102, Active, not recruiting, Pierre Fabre Dermo Cosmetique

In this single-center retrospective study, children with a median age 5.1 years (range, 2.0-11.1 years) with R/R HR-NB who were treated with >5 cycles of dinutuximab beta (10 mg/m2/day for 10-days per 35-day cycle), granulocyte-macrophage colony-stimulating factor (GM-CSF) and isotretinoin, plus chemotherapy, were included. No immune-related deaths occurred. Overall, cycles beyond the standard 5 cycles of dinutuximab beta with chemoimmunotherapy were effective and tolerable in pediatric patients with R/R HR-NB, demonstrating improved response and survival outcomes.

P=N/A, N=54, Recruiting, Uşak University

P1, N=18, Active, not recruiting, Dwight Owen | Trial primary completion date: Jan 2026 --> Sep 2025

P1, N=72, Active, not recruiting, Wake Forest University Health Sciences | Recruiting --> Active, not recruiting | Trial primary completion date: Feb 2026 --> Jun 2025

P2, N=76, Terminated, Mario Negri Institute for Pharmacological Research | N=112 --> 76 | Trial completion date: Sep 2024 --> Jan 2025 | Recruiting --> Terminated | Trial primary completion date: Aug 2024 --> Jan 2025; Low enrolment rate

P2, N=151, Recruiting, M.D. Anderson Cancer Center | Trial completion date: Dec 2025 --> Dec 2027 | Trial primary completion date: Dec 2025 --> Dec 2027

Despite 3 years of acitretin therapy, surgical excisions, imiquimod and repeated cryotherapy, the lesions remained poorly controlled. This case, along with her sister's experience, highlights oral methotrexate as a potential therapeutic option for refractory cases. Further studies are needed to explore its role in the management of this challenging condition.

The condition was refractory to initial methotrexate and isotretinoin therapy. We report a rare and clinically challenging case of RDD diagnosed with the aid of histopathology and immunohistochemistry. Additionally, we emphasize the role of a combined approach of serial surgical excisions and systemic dapsone therapy.